Obese or diabetic? Getting US visa may become harder
Werte in diesem Artikel
SEATTLE — If you’re obese or diabetic, moving to the United States could soon become much harder. Under the new Trump administration guidance, immigrants with chronic conditions such as diabetes or obesity may be denied U.S. immigrant visas as officials expand medical screening to include non-contagious illnesses. The policy, sent to U.S. embassies and consulates worldwide, instructs visa officers to assess whether applicants with long-term or costly health issues might become a “public burden,” tightening health-based grounds for immigration. The directive coincided with President Donald Trump’s announcement Thursday to cut consumer costs for popular weight-loss drugs. On the same day he pledged to make medications like Ozempic and Wegovy more affordable for Americans, the administration issued new instructions that could make it harder for obese foreigners or those with diabetes to qualify for immigrant visas. According to a U.S. State Department cable, consular officers are now required to consider a wide range of chronic conditions including cardiovascular and respiratoryWeiter zum vollständigen Artikel bei Korea Times
Übrigens: Visa und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Visa
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Visa
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Korea Times
Nachrichten zu Visa Inc.
Analysen zu Visa Inc.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.10.2025 | Visa Overweight | JP Morgan Chase & Co. | |
| 17.07.2025 | Visa Outperform | RBC Capital Markets | |
| 17.07.2025 | Visa Outperform | Bernstein Research | |
| 30.04.2025 | Visa Buy | UBS AG | |
| 30.04.2025 | Visa Overweight | JP Morgan Chase & Co. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.10.2025 | Visa Overweight | JP Morgan Chase & Co. | |
| 17.07.2025 | Visa Outperform | RBC Capital Markets | |
| 17.07.2025 | Visa Outperform | Bernstein Research | |
| 30.04.2025 | Visa Buy | UBS AG | |
| 30.04.2025 | Visa Overweight | JP Morgan Chase & Co. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 18.05.2018 | Visa Neutral | UBS AG | |
| 15.04.2016 | Visa Neutral | Compass Point | |
| 24.07.2015 | Visa Hold | Topeka Capital Markets | |
| 24.07.2015 | Visa Mkt Perform | FBR Capital | |
| 30.01.2015 | Visa Mkt Perform | FBR Capital |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.11.2012 | Visa sell | UBS AG | |
| 12.09.2012 | Visa sell | UBS AG | |
| 26.07.2012 | Visa sell | UBS AG | |
| 09.07.2012 | Visa sell | UBS AG | |
| 11.12.2008 | Visa underperform | Cowen and Company, LLC |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Visa Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen